| 23.46 0.03 (0.13%) | 06-09 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 27.41 | 1-year : | 32.01 |
| Resists | First : | 23.46 | Second : | 27.41 |
| Pivot price | 23.43  |
|||
| Supports | First : | 22.45 |
Second : | 21.81 |
| MAs | MA(5) : | 23.45 |
MA(20) : | 23.36 |
| MA(100) : | 16.67 |
MA(250) : | 13.48 |
|
| MACD | MACD : | 0.8  |
Signal : | 1 |
| %K %D | K(14,3) : | 81.8 |
D(3) : | 84.2 |
| RSI | RSI(14): 83.5 |
|||
| 52-week | High : | 23.46 | Low : | 8.6 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ ASRT ] has closed below upper band by 24.9%. Bollinger Bands are 97.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 10 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 23.48 - 23.62 | 23.62 - 23.76 |
| Low: | 23.09 - 23.26 | 23.26 - 23.42 |
| Close: | 23.2 - 23.45 | 23.45 - 23.69 |
Assertio Holdings, Inc. is a specialized pharmaceutical company focused on developing and commercializing therapeutic solutions across key medical domains, including neurology, hospital care, and pain and inflammation management. Among its portfolio, Assertio offers INDOCIN, available as both an oral solution and a suppository. This medication addresses conditions such as moderate to severe rheumatoid arthritis (including acute flare-ups), ankylosing spondylitis, osteoarthritis, acute painful shoulder, and gouty arthritis. The company's offerings also encompass CAMBIA, an NSAID specifically formulated to alleviate symptoms associated with migraine headaches, including nausea, light sensitivity (photophobia), and sound sensitivity (phonophobia). Zipsor, another NSAID, is indicated for managing mild to moderate acute pain. For more significant short-term pain relief, SPRIX, also an NSAID, provides analgesia comparable to opioid-level treatments for moderate to moderately severe pain. Rounding out its product line is Otrexup, a prescription methotrexate delivered via a convenient single-dose auto-injector. This therapy targets severe, active rheumatoid arthritis in adults and active polyarticular juvenile idiopathic arthritis in pediatric patients. Initially incorporated as Assertio Therapeutics, Inc. in 1995, the organization rebranded to Assertio Holdings, Inc. in May 2020 and maintains its corporate headquarters in Lake Forest, Illinois.
Tue, 09 Jun 2026
Are SUNE, RLYB, ASRT, TMHC Obtaining Fair Deals for their Shareholders? - TradingView
Sat, 06 Jun 2026
Nantahala Capital Management, LLC Sells Out of Assertio Holdings Inc - GuruFocus
Fri, 05 Jun 2026
ASSERTIO HOLDINGS INC (ASRT) Stock Chart - ChartMill
Tue, 02 Jun 2026
Assertio Holdings (ASRT) amendment shows Nantahala and managers report 0% ownership - Stock Titan
Tue, 26 May 2026
ASRT - Assertio Holdings Inc Stock Price and Quote - Finviz
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 6 (M) |
| Shares Float | 6 (M) |
| Held by Insiders | 1.9 (%) |
| Held by Institutions | 39.9 (%) |
| Shares Short | 249 (K) |
| Shares Short P.Month | 287 (K) |
| EPS | -5.56 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 11.72 |
| Profit Margin | -35 % |
| Operating Margin | -186 % |
| Return on Assets (ttm) | -5.8 % |
| Return on Equity (ttm) | -38.8 % |
| Qtrly Rev. Growth | -62.5 % |
| Gross Profit (p.s.) | 11.12 |
| Sales Per Share | 15.81 |
| EBITDA (p.s.) | 0.59 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -7 (M) |
| Levered Free Cash Flow | 8 (M) |
| PE Ratio | -4.23 |
| PEG Ratio | 0.8 |
| Price to Book value | 2 |
| Price to Sales | 1.48 |
| Price to Cash Flow | -21.41 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|